FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2565561569> ?p ?o ?g. }

• W2565561569 endingPage "551" @default.
• W2565561569 startingPage "544" @default.
• W2565561569 abstract "Purpose We compared the efficacy of ofatumumab (O) versus rituximab (R) in combination with cisplatin, cytarabine, and dexamethasone (DHAP) salvage treatment, followed by autologous stem-cell transplantation (ASCT) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients and Methods Patients with CD20 + DLBCL age ≥ 18 years who had experienced their first relapse or who were refractory to first-line R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)–like treatment were randomly assigned between three cycles of R-DHAP or O-DHAP. Either O 1,000 mg or R 375 mg/m 2 was administered for a total of four infusions (days 1 and 8 of cycle 1; day 1 of cycles 2 and 3 of DHAP). Patients who experienced a response after two cycles of treatment received the third cycle, followed by high-dose therapy and ASCT. Primary end point was progression-free survival (PFS), with failure to achieve a response after cycle 2 included as an event. Results Between March 2010 and December 2013, 447 patients were randomly assigned. Median age was 57 years (range, 18 to 83 years); 17% were age ≥ 65 years; 63% had stage III and IV disease; 71% did not achieve complete response (CR) or experience response for < 1 year on first-line R-CHOP. Response rate for O-DHAP was 38% (CR, 15%) versus 42% (CR, 22%) for R-DHAP. ASCT on protocol was completed by 74 patients (33%) in the O arm and 83 patients (37%) in the R arm. PFS, event-free survival, and overall survival were not significantly different between O-DHAP versus R-DHAP: PFS at 2 years was 24% versus 26% (hazard ratio [HR], 1.12; 95% CI, 0.89 to 1.42; P = .33); event-free survival at 2 years was 16% versus 18% (HR, 1.10; P = .35); and overall survival at 2 years was 41% versus 38% (HR, 0.90; P = .38). Positron emission tomography negativity before ASCT was highly predictive for superior outcome. Conclusion No difference in efficacy was found between O-DHAP and R-DHAP as salvage treatment of relapsed or refractory DLBCL." @default.
• W2565561569 created "2017-01-06" @default.
• W2565561569 creator A5005323855 @default.
• W2565561569 creator A5011398209 @default.
• W2565561569 creator A5015509689 @default.
• W2565561569 creator A5021435946 @default.
• W2565561569 creator A5022624109 @default.
• W2565561569 creator A5025565506 @default.
• W2565561569 creator A5027520859 @default.
• W2565561569 creator A5040082277 @default.
• W2565561569 creator A5040802981 @default.
• W2565561569 creator A5043162057 @default.
• W2565561569 creator A5049461398 @default.
• W2565561569 creator A5051888634 @default.
• W2565561569 creator A5053161231 @default.
• W2565561569 creator A5068071215 @default.
• W2565561569 creator A5069477380 @default.
• W2565561569 creator A5071885891 @default.
• W2565561569 creator A5088607533 @default.
• W2565561569 creator A5091631694 @default.
• W2565561569 date "2017-02-10" @default.
• W2565561569 modified "2023-10-14" @default.
• W2565561569 title "Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study" @default.
• W2565561569 cites W1500781157 @default.
• W2565561569 cites W1721657566 @default.
• W2565561569 cites W1997353354 @default.
• W2565561569 cites W2016973656 @default.
• W2565561569 cites W2029421916 @default.
• W2565561569 cites W2029915215 @default.
• W2565561569 cites W2044947137 @default.
• W2565561569 cites W2058015212 @default.
• W2565561569 cites W2088332148 @default.
• W2565561569 cites W2100158834 @default.
• W2565561569 cites W2106928992 @default.
• W2565561569 cites W2114816706 @default.
• W2565561569 cites W2122725450 @default.
• W2565561569 cites W2126529136 @default.
• W2565561569 cites W2133201432 @default.
• W2565561569 cites W2133345449 @default.
• W2565561569 cites W2137348614 @default.
• W2565561569 cites W2138874270 @default.
• W2565561569 cites W2139401596 @default.
• W2565561569 cites W2142724147 @default.
• W2565561569 cites W2145304413 @default.
• W2565561569 cites W2150587745 @default.
• W2565561569 cites W2153665789 @default.
• W2565561569 cites W2160305510 @default.
• W2565561569 cites W2167571754 @default.
• W2565561569 doi "https://doi.org/10.1200/jco.2016.69.0198" @default.
• W2565561569 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28029326" @default.
• W2565561569 hasPublicationYear "2017" @default.
• W2565561569 type Work @default.
• W2565561569 sameAs 2565561569 @default.
• W2565561569 citedByCount "152" @default.
• W2565561569 countsByYear W25655615692015 @default.
• W2565561569 countsByYear W25655615692016 @default.
• W2565561569 countsByYear W25655615692017 @default.
• W2565561569 countsByYear W25655615692018 @default.
• W2565561569 countsByYear W25655615692019 @default.
• W2565561569 countsByYear W25655615692020 @default.
• W2565561569 countsByYear W25655615692021 @default.
• W2565561569 countsByYear W25655615692022 @default.
• W2565561569 countsByYear W25655615692023 @default.
• W2565561569 crossrefType "journal-article" @default.
• W2565561569 hasAuthorship W2565561569A5005323855 @default.
• W2565561569 hasAuthorship W2565561569A5011398209 @default.
• W2565561569 hasAuthorship W2565561569A5015509689 @default.
• W2565561569 hasAuthorship W2565561569A5021435946 @default.
• W2565561569 hasAuthorship W2565561569A5022624109 @default.
• W2565561569 hasAuthorship W2565561569A5025565506 @default.
• W2565561569 hasAuthorship W2565561569A5027520859 @default.
• W2565561569 hasAuthorship W2565561569A5040082277 @default.
• W2565561569 hasAuthorship W2565561569A5040802981 @default.
• W2565561569 hasAuthorship W2565561569A5043162057 @default.
• W2565561569 hasAuthorship W2565561569A5049461398 @default.
• W2565561569 hasAuthorship W2565561569A5051888634 @default.
• W2565561569 hasAuthorship W2565561569A5053161231 @default.
• W2565561569 hasAuthorship W2565561569A5068071215 @default.
• W2565561569 hasAuthorship W2565561569A5069477380 @default.
• W2565561569 hasAuthorship W2565561569A5071885891 @default.
• W2565561569 hasAuthorship W2565561569A5088607533 @default.
• W2565561569 hasAuthorship W2565561569A5091631694 @default.
• W2565561569 hasConcept C126322002 @default.
• W2565561569 hasConcept C126894567 @default.
• W2565561569 hasConcept C141071460 @default.
• W2565561569 hasConcept C143998085 @default.
• W2565561569 hasConcept C181199279 @default.
• W2565561569 hasConcept C185592680 @default.
• W2565561569 hasConcept C2776694085 @default.
• W2565561569 hasConcept C2776755627 @default.
• W2565561569 hasConcept C2778559949 @default.
• W2565561569 hasConcept C2778714382 @default.
• W2565561569 hasConcept C2778822529 @default.
• W2565561569 hasConcept C2779050716 @default.
• W2565561569 hasConcept C2779338263 @default.
• W2565561569 hasConcept C2779429289 @default.
• W2565561569 hasConcept C2779617269 @default.
• W2565561569 hasConcept C2780653079 @default.

• next